Truist Financial analyst Jailendra Singh reiterated a Hold rating on GoodRx Holdings (GDRX – Research Report) today. The company’s shares closed yesterday at $7.27.
Singh covers the Healthcare sector, focusing on stocks such as IQVIA Holdings, Evolent Health, and R1 RCM. According to TipRanks, Singh has an average return of -14.8% and a 33.52% success rate on recommended stocks.
In addition to Truist Financial, GoodRx Holdings also received a Hold from Morgan Stanley’s Craig Hettenbach in a report issued today. However, on the same day, KeyBanc reiterated a Buy rating on GoodRx Holdings (NASDAQ: GDRX).
Based on GoodRx Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $196.64 million and a GAAP net loss of $25.87 million. In comparison, last year the company earned a revenue of $184.11 million and had a GAAP net loss of $1.97 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GoodRx Holdings (GDRX) Company Description:
GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.
